One in five adults in the U.S. live with a mental illness and the COVID-19 pandemic has made the situation worse. The biotech industry is stepping in to address the issue, leading to the emergence of many mental health companies. There were at least 163 drugs targeting mental health under review or in the clinic according to a report last year from Pharmaceutical Research and Manufacturers of America. This article discusses eight such companies: Alto Neuroscience, atai Life Sciences, Axsome, Compass Pathways, Freedom Biosciences, MindMed, Relmada Therapeutics, and Vistagen.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
